Belchatow

Researchers are evaluating the effectiveness and safety of SPT-300 GlyphAllo, a drug being studied for adults with major depressive disorder MDD, including those with or without anxious distress. This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess how well SPT-300 works and how well participants tolerate it. Participants will be randomly assigned to receive either SPT-300 capsules or a matching placebo once daily for 42 days. The study compares these two groups to understand the impact of SPT-300 as a monotherapy treatment for MDD. During the study, participants will be assessed for changes in depression severity using the Hamilton Depression Rating Scale-17 HAM-D-17 from the start to day 42 of treatment. Additional evaluations include clinical global impression severity scores. The trial includes monitoring for safety, tolerability, and other health measures throughout the 42-day treatment period.

Anterior Cruciate Ligament ACL Degeneratio Mucosa is a condition caused by mucoid degeneration of the ACL, leading to impaired daily function. The exact cause of this condition is unknown. Researchers are studying a surgical technique called ACL decompression, which involves making longitudinal incisions and removing extrafibrous mucoid tissue to address this problem. The study focuses on patients with ACL Degeneratio Mucosa who have decided to undergo surgical treatment. This treatment involves the decompression procedure applied to the affected ligament. The study does not mention comparison groups or placebos, as it is observational in nature. Participants will be followed for up to 24 months, during which their knee function will be closely monitored. Assessments include measuring range of motion, knee stability in different directions, and functional scores using the International Knee Documentation Committee Questionnaire IKDC and the Knee Injury and Osteoarthritis Outcome Score KOOS. These evaluations occur at 12 and 24 months after treatment to track recovery and knee performance.

Researchers are evaluating the outcomes of Double-bundle Posterior Cruciate Ligament Reconstruction DB-PCLR for patients with Posterior Cruciate Ligament PCL tears. This observational study aims to assess whether DB-PCLR, which reconstructs both the anterolateral and posteromedial bundles of the PCL, can improve patient results compared to the single-bundle procedure. The study is led by Konrad Malinowski MD and focuses on patients with grade III symptomatic posterior instability. Participants will undergo the DB-PCLR procedure, which involves reconstructing both PCL bundles. The study monitors patients treated with this method to evaluate knee stability and function over time. There are no comparison groups, as this is an observational assessment of patients receiving DB-PCLR. During the study, participants will be followed up at 12 and 24 months after surgery. Researchers will assess knee posterior translatory stability using clinical tests such as the posterior sag, drawer, Lachman tests, and stress X-rays, as well as knee internal rotation stability. Functional outcomes will be measured using questionnaires like the International Knee Documentation Committee IKDC and the Knee injury and Osteoarthritis Outcome Score KOOS. Additionally, retear rates and range of motion ROM will be evaluated. The study will provide detailed follow-up on knee function and stability for up to two years post-treatment.

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and cardiovascular disease but no history of heart failure. The study aims to assess whether this combination can help reduce cardiovascular risks compared to a placebo with empagliflozin. This Phase III trial involves adults with these conditions who are already receiving treatment for them. Participants are randomly assigned to one of two groups. One group takes vicadrostat and empagliflozin tablets daily, while the other group takes placebo tablets that look like vicadrostat but have no active medicine, alongside empagliflozin. Treatment lasts from two and a half years up to four years and three months. All participants continue their usual medications for diabetes, blood pressure, and heart disease during the study. Throughout the study, lasting up to four years and three months, participants visit the study site regularly for health checks and blood samples. Doctors monitor cardiovascular events and any side effects experienced. The main outcome measured is the time until the first cardiovascular death or heart failure event. Other health indicators like blood pressure and kidney function are also tracked to understand the effects of the treatment combination.

Researchers are evaluating the long-term safety and tolerability of NBI-1065845 as an additional treatment for adults with Major Depressive Disorder MDD. This Phase 3, open-label study focuses on participants who have a primary diagnosis of recurrent moderate or severe MDD or persistent depressive disorder and have had an inadequate response to oral antidepressant treatments in their current depressive episode. Participants will receive NBI-1065845 tablets taken orally once daily as an adjunctive therapy alongside their ongoing antidepressant treatments. The study is designed as a single-group, open-label trial without placebo or comparison groups. The treatment period and follow-up extend over 52 weeks, during which safety and tolerability will be closely monitored. Throughout the study, participants will be assessed for treatment-emergent adverse events TEAEs from baseline through Week 52. Participants must be willing and able to comply with all study procedures and restrictions, including regular visits and evaluations determined by the investigators. The overall study duration allows for comprehensive monitoring of safety outcomes and participant well-being.

Lateral patellar dislocation often results in injury to the medial patellofemoral ligament MPFL, leading to ongoing instability of the knee. Researchers are evaluating the outcomes of reconstructing the MPFL using a fascia lata allograft with isometry assessment, combined with the Elmslie-Trillat tibial tuberosity osteotomy procedure. This study aims to assess how well this combined surgical approach improves knee stability and function in affected patients. Participants will undergo the MPFL reconstruction with fascia lata allograft, guided by isometry assessment, along with the Elmslie-Trillat tibial tuberosity osteotomy. Any additional patellofemoral lesions found during surgery will also be managed. This is a procedural study focused on this combined surgical treatment without a comparison group. During the study, participants will be monitored at 12 and 24 months after surgery. Researchers will evaluate lateral patella stability using apprehension and lateral luxation tests at both time points. Functional assessments include the International Knee Documentation Committee Questionnaire and the Knee injury and Osteoarthritis Outcome Score, as well as range of motion measurements. These evaluations will help measure the success of the surgery and patient recovery over two years.

This research aims to assess the outcomes of treating Posteromedial Tibiofemoral Incongruence PMTFI, a condition where decreased curvature in the femoral metaphysis near the medial femoral condyle causes compression of the posterior horn of the medial meniscus PHMM during full knee flexion. This can lead to pain, snapping, discomfort, and worsening meniscus degeneration over time, especially during deep knee bending. The study evaluates a published arthroscopic technique designed to correct this incongruence with minimal necessary intervention, confirming the need for repair during surgery. The study involves a single treatment group receiving the PMTFI treatment following the specific published arthroscopic method. This surgical procedure aims to correct the anatomical incongruence that causes PHMM compression, potentially improving symptoms when conservative treatments have failed. There is no placebo or alternate comparison group mentioned. Participants will be monitored for up to 24 months after treatment. Researchers will assess pain presence during full knee flexion at 12 and 24 months, along with functional outcomes using the International Knee Documentation Committee Questionnaire IKDC and the Knee injury and Osteoarthritis Outcome Score KOOS at the same intervals. The study includes clinical evaluations, imaging confirmation, and arthroscopic assessment, focusing on symptom relief and functional improvement over time.